Lexeo Therapeutics, Inc. (LXEO)
(Real Time Quote from BATS)
$12.02 USD
+0.33 (2.82%)
Updated Aug 15, 2024 03:55 PM ET
After-Market: $12.13 +0.11 (0.92%) 4:18 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
LXEO 12.02 +0.33(2.82%)
Will LXEO be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for LXEO based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for LXEO
Biotech Stock Roundup: LXRX Up on Regulatory Update, SAVA, LXEO Down on Updates
Lexeo (LXEO) Down Despite Upbeat Rare Disease Gene Therapy Data
LXEO: What are Zacks experts saying now?
Zacks Private Portfolio Services
What Makes Lexeo Therapeutics, Inc. (LXEO) a New Buy Stock
Wall Street Analysts Think Lexeo Therapeutics, Inc. (LXEO) Could Surge 57.82%: Read This Before Placing a Bet
Other News for LXEO
Buy Rating on Lexeo Therapeutics: Promising Clinical Advancements and Strategic FDA Engagement
Analysts Conflicted on These Healthcare Names: Amylyx Pharmaceuticals Inc (AMLX), Taysha Gene Therapies (TSHA) and Lexeo Therapeutics, Inc. (LXEO)
Buy Rating for Lexeo Therapeutics Backed by Strong Finances and Promising Clinical Trials
Lexeo Therapeutics, Inc. (LXEO) Receives a Buy from RBC Capital
Buy Rating Affirmed for Lexeo Therapeutics Amid Anticipated Catalysts and Solid Financials